Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Quarterly Earnings Results, Beats Expectations By $0.29 EPS

Amphastar Pharmaceuticals (NASDAQ:AMPH) posted its earnings results on Thursday. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.29, FiscalAI reports. The business had revenue of $183.90 million during the quarter, compared to the consensus estimate of $179.92 million. Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%.

Here are the key takeaways from Amphastar Pharmaceuticals’ conference call:

• Second-quarter revenue rose 5% year over year to $183.9 million, with gross margin improving to 51% as recently launched products, including ipratropium bromide, teriparatide, and iron sucrose, contributed higher-margin sales. Management maintained its 2026 corporate sales-growth outlook of mid-single-digit to high-single-digit growth.
• Ipratropium bromide launched successfully in April, generating $8.4 million in quarterly sales, and management said the product is approaching its targeted 50%–80% market-share range. BAQSIMI prescriptions also increased 17% year over year, and the product exceeded its annual sales milestone, triggering a $100 million payment to Eli Lilly.
• IMS received an FDA warning letter and expects an additional $2 million to $3 million per quarter in remediation expenses for the next several quarters, along with somewhat slower sales and possible production delays. Management does not currently expect a material impact on overall operations and said manufacturing and distribution are continuing.
• Glucagon sales fell 42% year over year to $11.9 million because of intensified competition; management expects the decline to moderate but does not anticipate the product returning to growth. BAQSIMI sales also declined 3% because of lower pricing, rebates, and 340B discounts despite higher prescription volumes.
• The company advanced several pipeline programs, including initiating a Phase I trial for AMP-101 epinephrine nasal spray and continuing preparations for its insulin aspart biosimilar, which remains on track for a potential 2027 launch subject to approval. Amphastar also repurchased approximately $45 million of shares during the quarter.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ:AMPH traded down $0.43 during midday trading on Thursday, hitting $19.81. The stock had a trading volume of 526,646 shares, compared to its average volume of 406,020. Amphastar Pharmaceuticals has a 1 year low of $16.65 and a 1 year high of $31.26. The company has a current ratio of 3.85, a quick ratio of 2.82 and a debt-to-equity ratio of 0.79. The stock has a 50 day moving average price of $19.63 and a two-hundred day moving average price of $21.40. The company has a market capitalization of $873.42 million, a PE ratio of 11.93, a P/E/G ratio of 4.27 and a beta of 0.89.

Analyst Ratings Changes

AMPH has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, July 8th. Jefferies Financial Group reissued a “hold” rating and issued a $22.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Friday, May 8th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $19.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a research report on Thursday, May 14th. Finally, Bank of America reiterated an “underperform” rating and set a $20.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, June 29th. Six research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Amphastar Pharmaceuticals currently has a consensus rating of “Reduce” and a consensus price target of $22.00.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in AMPH. Quarry LP purchased a new stake in Amphastar Pharmaceuticals in the 3rd quarter valued at approximately $32,000. Quadrant Capital Group LLC purchased a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter worth approximately $82,000. Tower Research Capital LLC TRC raised its stake in shares of Amphastar Pharmaceuticals by 263.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,583 shares of the company’s stock worth $82,000 after buying an additional 2,596 shares in the last quarter. Canada Pension Plan Investment Board lifted its holdings in shares of Amphastar Pharmaceuticals by 55.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 4,200 shares of the company’s stock valued at $96,000 after buying an additional 1,500 shares during the period. Finally, Corient IA LLC purchased a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter valued at approximately $201,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.